Results 191 to 200 of about 4,796,691 (248)

Leukemia inhibitory factor (LIF) receptor amplifies pathogenic activation of fibroblasts in lung fibrosis. [PDF]

Proc Natl Acad Sci U S A
Nguyen HN, Jeong Y, Kim Y, Kamiya M, Kim Y, Athar H, Castaldi PJ, Hersh CP, Menon JA, Wong J, Chan I, Oldham WM, Padera RF, Sharma NS, Sholl LM, Vivero M, Watts GFM, Knipe RS, Black KE, Hariri LP, Yun JH, Merriam LT, Yuan K, Kim EY, Brenner MB.   +24 more
europepmc   +1 more source

AI‐Driven Cancer Multi‐Omics: A Review From the Data Pipeline Perspective

Advanced Intelligent Discovery, EarlyView.
The exponential growth of cancer multi‐omics data brings opportunities and challenges for precision oncology. This review systematically examines AI's role in addressing these challenges, covering generative models, integration architectures, Explainable AI for clinical trust, clinical applications, and key directions for clinical translation.
Shilong Liu, Shunxiang Li, Kun Qian
wiley   +1 more source

Azithromycin prevents implantation failure via up-regulation of leukemia inhibitory factor in endotoxemic pregnant rats. [PDF]

Iran J Basic Med Sci
Sonmez G, Tufan Akarslan O, Culha MH, Parlak TM, Dik B, Er A.   +5 more
europepmc   +1 more source

Targeting B‐Cell‐Activating Factor and Its Receptor in Immune Thrombocytopenia and Warm Autoimmune Hemolytic Anemia

American Journal of Hematology, EarlyView.
ABSTRACT Current treatments for immune thrombocytopenia (ITP) and warm autoimmune hemolytic anemia (wAIHA), rare autoimmune diseases in which autoreactive B cells play a major role, can lead to high response rates; however, for many patients these responses are not durable or maintained after treatment discontinuation.
Matthieu Mahévas, Nichola Cooper, Vickie McDonald, Karina Yazdanbakhsh, Wilma Barcellini   +4 more
wiley   +1 more source

Activation of Bradykinin B₂ Receptors in Astrocytes Stimulates the Release of Leukemia Inhibitory Factor for Autocrine and Paracrine Signaling. [PDF]

Int J Mol Sci
Lu Y, Gu Y, Chan ASL, Yung Y, Wong YH.
europepmc   +1 more source

Real‐World Outcomes of Midostaurin Plus Intensive Chemotherapy in FLT3‐Mutated AML: The PETHRATIFY Study

American Journal of Hematology, EarlyView.
ABSTRACT Mutations in FLT3 are present in approximately 30% of patients with AML. The addition of midostaurin (MIDO) to intensive chemotherapy (IC) became standard of care following the RATIFY trial, but comprehensive real‐world data spanning the full adult age spectrum and including both FLT3‐ITD and FLT3‐TKD mutations remain limited.
Mónica Alejandra Romero Riquelme, Gaspar Aspas Requena, Pilar Lloret‐Madrid, Cristina Gil, Eliana Aguiar, Mar Tormo, Teresa del Bernal del Castillo, Eduardo Rodríguez Arbolí, Josefina Serrano, Joaquín Sánchez‐García, Carlos Rodríguez‐Medina, José Mário Mariz, Rosa Ayala, Joaquín Martínez‐López, María Luz Amigo, Susana Vives, Lorenzo Algarra Algarra, Raimundo García Boyero, Joana Brioso, Tamara Castaño, Juan M. Bergua Burgués, Olga Salamero, María Francisca Bass Maturana, Mercedes Colorado, María García Fortes, María José Sayas Lloris, Belén Vidriales Vicente, Carmen Chillón, Esther Pérez Santaolalla, María Dolores Madrigal, Jorge Labrador Gómez, María José García Pérez, Soledad Casado Calderón, Manuel Pérez Encinas, Amaia Balerdi Malcorra, María Solé Rodríguez, Lara María Gómez García, Pilar Herrera Puente, Olga Arce Fernández, Manuel Barrios García, Víctor Noriega, Rosa Fernández, Mamen Mateos, Carolina Lacalzada, Ágata Almela Gallego, María Carmen García Garay, Carmen Couto, José Antonio Pérez‐Simón, Eva Barragán González, Pau Montesinos   +49 more
wiley   +1 more source

The Role of Leukemia Inhibitory Factor in Cardiovascular Disease: Signaling in Inflammation, Coagulation, and Angiogenesis. [PDF]

J Tehran Heart Cent
Rezaeeyan H, Moghimian-Boroujeni B, Abdolalian M, Javan M.   +3 more
europepmc   +1 more source

Phase II Study of Posttransplant Cyclophosphamide‐Based Graft‐Versus‐Host Disease Prophylaxis After HLA‐Mismatched Unrelated Donor Reduced Intensity Transplantation: Results From the ACCESS Trial Expansion Cohort

American Journal of Hematology, EarlyView.
ABSTRACT Posttransplant cyclophosphamide (PTCy) to prevent graft‐versus‐host disease (GVHD) improves outcomes in recipients of HLA mismatched unrelated donor (MMUD) allogeneic hematopoietic cell transplantation (allo HCT). Outcomes of MMUD HCT using PTCy in patients requiring reduced intensity or non‐myeloablative conditioning (RIC/NMA) are not well ...
Brian C. Shaffer, Monzr M. Al Malki, Antonio Martin Jimenez Jimenez, Joseph Stanek, Stephanie Bo‐Subait, Brent R. Logan, Jianqun Kou, Erin Leckrone, Heather E. Stefanski, Stephen R. Spellman, Craig Malmberg, Medhat Askar, Rachel Cusatis, Dipenkumar Modi, Farhad Khimani, Mehdi Hamadani, Martin Maiers, Rachel Cook, Karen Ballen, Javier Bolaños‐Meade, Uttam Rao, Jordan Milner, Ramzi Abboud, Katarzyna Jamieson, George Carrum, Bhagirathbhai Dholaria, William J. Hogan, Ran Reshef, Satyajit Kosuri, Alison Loren, Karilyn Larkin, Sally Arai, Muna Qayed, Sung Won Choi, Larisa Broglie, Jeffery J. Auletta, Bronwen E. Shaw, Steven M. Devine, Mahasweta Gooptu   +38 more
wiley   +1 more source

Human Recombinant Interleukin-6 and Leukemia Inhibitory Factor Improve Inner Cell Mass Cell Number but Lack Cryoprotective Activities on In Vitro-Produced Bovine Blastocysts. [PDF]

Animals (Basel)
Oliver MA, Alward KJ, Rhoads ML, Ealy AD.   +3 more
europepmc   +1 more source